Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...
The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...
We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...
Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...
Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...
Fondazione Telethon ETS' Waskyra has become the first gene therapy in the US for patients with Wiskott-Aldrich syndrome (WAS) ...
The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...
MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...
The managing director of Novo Nordisk India on Ozempic’s delayed launch in India, leading the fight against diabetes and ...
A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.
Pharma companies need to move beyond the “weight-loss Olympics” and focus on more durable treatments with fewer side effects, ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback